Testimony Before the FDA’s Drug Safety and Risk Management Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee Regarding Reformulated Oxycontin
In testimony before a joint meeting of the Food and Drug Administration’s (FDA’s) Drug Safety and Risk Management Advisory Committee Anesthetic and Analgesic Drug Products Advisory Committee, Public Citizen emphasized that there is a serious question as to whether introducing abuse deterrent opioids such as reformulated Oxycontin (oxycodone) may have worsened overall public health.
See Public Citizen’s other work on opioid drug issues.
See Public Citizen’s other work on oxycodone (Oxycontin).